

Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, February 24, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of April 1, 2021.

1. Corporate Reorganization (see attached organization chart)

(1) Reorganization of the Global Development Division

The Regulatory Affairs Supervisor will be progressively dissolved, and the affiliated organization will be directly under the Global Development Division.

(2) New establishment of the Vaccine Business Department

The Vaccine Business Department will be newly established under the Integrated Disease Care Division as an organization to promptly launch the vaccine business and prepare for the supply and distribution of vaccines.

2. Personnel Reassignment (Effective; April 1, 2021)

New Position	Name	Present Position
Integrated Disease Care Division		
Vice president, Vaccine Business Department	Norio Tamura	Vice president, Regulatory Affairs Supervisor
UMN Pharma Inc.		
Chairman	Fumihisa Nakata	President
President	Kazufumi Katayama	UMN Pharma Inc.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and

Press Release



changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

SHIONOGI Divisions (April 1, 2021)

